Novo Nordisk has launched Ozempic, its injectable semaglutide formulation for Type 2 diabetes, in the Indian market, with the company positioning the drug as a key addition to its diabetes portfolio alongside its recently introduced obesity treatment Wegovy.

Vikrant Shrotriya, Managing Director of Novo Nordisk India, told CNBC-TV18 that the company is introducing Ozempic in three strengths, “0.25, 0.5 and 1 milligramme for the benefit of type two diabetes patients.” He clarified that the higher 2.4 mg strength, already available in India, is exclusively meant for obesity.

On why the company is doubling down on injectables when it already offers the oral semaglutide brand Rybelsus, Shrotriya said the decision reflects evolving patient preferences rather than any slowdown in oral uptake.

See Full Page